A named analyst is the cheapest quality signal in this trade
What the Journal asks when a document arrives unsigned, and what the answers have been.
Independent testing
Page 21 of 27 of this archive, newest first.
Independent analysis puts a SSA retatrutide lot at 95.4%, against 93.5% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
Six tells, in order of how quickly they can be checked
A blank certificate with the numbers left editable is an ordinary internal document. Its circulation as a finished record is the problem.
VendorInvestigate result on a Hong Kong dulaglutide lot lands 3.1 points below the supplier’s figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
The question no chromatogram has ever answered
The Journal has read several hundred certificates from twenty companies. We set out what the documents actually cover, and what a reader is filling in from imagination.
PeptideMeter result on a Wuhan dulaglutide lot lands 1.8 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
Why a result on one vial says less than the trade needs it to
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Independent analysis puts a TFC mazdutide lot at 98.1%, against 94.2% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
VendorInvestigate result on a Tianjin tirzepatide lot lands 0.7 points below the supplier’s figure
The report states the gradient, the wavelength and the integration threshold, which is more than most.
The badge economy, and what it is actually certifying
The Journal does not treat a badge as evidence and states so wherever it reports one.
What a split-sample exercise can establish, and what it cannot
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
How a claim degrades between the bench and the listing
Every step between the laboratory report and the product page removes information, and the badge is the last step.
How a claim degrades between the bench and the listing
What a verification mark would have to carry to be checkable: a date, a lot, a method, a submitter and a link to the report.
PeptideMeter result on a Suzhou retatrutide lot lands 2.2 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
Retest date, expiry date, and the two conventions being confused
What happens to traceability when bulk material is subdivided, repackaged and relabelled two or three times before sale.
Independent analysis puts a SWB orforglipron lot at 97.7%, against 94.2% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
Medutest result on a Shenzhen tirzepatide lot lands 1.0 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
Turnaround, cost and accreditation across the services this trade relies on
A compendial sterility test takes fourteen days of incubation and consumes the containers tested. That timescale is incompatible with the business model that made…
Medutest result on a Wuhan mazdutide lot lands 3.6 points below the supplier’s figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Independent analysis puts a MKM retatrutide lot at 95.5%, against 92.8% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.